IRIX vs GKOS vs ATRC vs TNDM vs HOLX

For growth investors, Glaukos Corporation (GKOS) is the stronger pick with 32.

3% revenue growth year-over-year, versus -6. 2% for IRIDEX Corporation (IRIX). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate Glaukos Corporation (GKOS) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Hologic, Inc.

is actually cheaper at 17. 2x.

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +74.

7%, compared to -86. 2% for IRIDEX Corporation (IRIX). Over 10 years, the gap is even starker: GKOS returned +454. 5% versus IRIX's -90. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus Tandem Diabetes Care, Inc. 's 1. 21β — meaning TNDM is approximately 167% more volatile than HOLX relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 3% for Tandem Diabetes Care, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Glaukos Corporation (GKOS) is pulling ahead at 32.

3% versus -6. 2% for IRIDEX Corporation (IRIX). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -106. 8% for Tandem Diabetes Care, Inc.. Over a 3-year CAGR, GKOS leads at 21. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -37. 0% for Glaukos Corporation — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -17. 1% for GKOS. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Hologic, Inc.

(HOLX) trades at 17. 2x forward P/E versus 428. 7x for AtriCure, Inc. — 411. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TNDM: 105. 4% to $31. 77.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), +124. 3% 10Y return). Both have compounded well over 10 years (HOLX: +124. 3%, TNDM: -79. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IRIX is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock; ATRC is a small-cap quality compounder stock; TNDM is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.